Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

ASCO 2018: highlights of urothelial cancer and prostate cancer.

Pichler R, Horninger W, Heidegger I.

Memo. 2018;11(4):284-290. doi: 10.1007/s12254-018-0422-0. Epub 2018 Jul 24. Review.

2.

FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.

Suzman DL, Agrawal S, Ning YM, Maher VE, Fernandes LL, Karuri S, Tang S, Sridhara R, Schroeder J, Goldberg KB, Ibrahim A, McKee AE, Pazdur R, Beaver JA.

Oncologist. 2018 Dec 12. pii: theoncologist.2018-0084. doi: 10.1634/theoncologist.2018-0084. [Epub ahead of print]

PMID:
30541754
3.

Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.

Beer TM, Hotte SJ, Saad F, Alekseev B, Matveev V, Fléchon A, Gravis G, Joly F, Chi KN, Malik Z, Blumenstein B, Stewart PS, Jacobs CA, Fizazi K.

Lancet Oncol. 2017 Nov;18(11):1532-1542. doi: 10.1016/S1470-2045(17)30605-8. Epub 2017 Oct 9.

PMID:
29033099
4.

Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.

Narayan V, Kahlmeyer A, Dahm P, Skoetz N, Risk MC, Bongiorno C, Patel N, Hwang EC, Jung JH, Gartlehner G, Kunath F.

Cochrane Database Syst Rev. 2018 Jul 23;7:CD012838. doi: 10.1002/14651858.CD012838.pub2. Review.

PMID:
30036453
5.

Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.

Katz H, Wassie E, Alsharedi M.

Med Oncol. 2017 Sep 1;34(10):170. doi: 10.1007/s12032-017-1029-8. Review.

PMID:
28864844
6.

Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens.

Perez-Gracia JL, Loriot Y, Rosenberg JE, Powles T, Necchi A, Hussain SA, Morales-Barrera R, Retz MM, Niegisch G, Durán I, Théodore C, Grande E, Shen X, Wang J, Nelson B, Derleth CL, van der Heijden MS.

Eur Urol. 2017 Dec 19. pii: S0302-2838(17)31015-1. doi: 10.1016/j.eururo.2017.11.023. [Epub ahead of print] Erratum in: Eur Urol. 2019 Mar;75(3):e82-e83.

PMID:
29273410
7.

Developments in urologic oncology "OncoForum": The best of 2017.

Gómez-Veiga F, Alcaraz-Asensio A, Burgos-Revilla J, Cózar-Olmo J.

Actas Urol Esp. 2018 Oct;42(8):488-498. doi: 10.1016/j.acuro.2018.06.001. Epub 2018 Jun 21. English, Spanish.

PMID:
29935800
8.

Emerging Therapies in Metastatic Prostate Cancer.

Sonnenburg DW, Morgans AK.

Curr Oncol Rep. 2018 Apr 11;20(6):46. doi: 10.1007/s11912-018-0692-z. Review.

PMID:
29644451
9.

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.

Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J.

Lancet Oncol. 2017 Nov;18(11):1483-1492. doi: 10.1016/S1470-2045(17)30616-2. Epub 2017 Sep 26.

PMID:
28967485
10.

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF; IMvigor210 Study Group.

Lancet. 2017 Jan 7;389(10064):67-76. doi: 10.1016/S0140-6736(16)32455-2. Epub 2016 Dec 8. Erratum in: Lancet. 2017 Aug 26;390(10097):848.

11.

Systematic Review of Immune Checkpoint Inhibition in Urological Cancers.

Rijnders M, de Wit R, Boormans JL, Lolkema MPJ, van der Veldt AAM.

Eur Urol. 2017 Sep;72(3):411-423. doi: 10.1016/j.eururo.2017.06.012. Epub 2017 Jun 20. Review.

PMID:
28645491
12.

[Atezolizumab (Tecentriq®): Activity, indication and modality of use in advanced or metastatic urinary bladder carcinoma].

Bernard-Tessier A, Bonnet C, Lavaud P, Gizzi M, Loriot Y, Massard C.

Bull Cancer. 2018 Feb;105(2):140-145. doi: 10.1016/j.bulcan.2017.10.030. Epub 2017 Dec 28. Review. French.

PMID:
29290331
13.

Neoadjuvant Chemotherapy for Patients with Muscle-invasive Urothelial Bladder Cancer Candidates for Curative Surgery: A Prospective Clinical Trial Based on Cisplatin Feasibility.

Schinzari G, Monterisi S, Pierconti F, Nazzicone G, Marandino L, Orlandi A, Racioppi M, Cassano A, Bassi P, Barone C, Rossi E.

Anticancer Res. 2017 Nov;37(11):6453-6458.

PMID:
29061832
14.

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.

Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, Dumez H, de Santis M, Théodore C, Leahy MG, Chester JD, Verbaeys A, Daugaard G, Wood L, Witjes JA, de Wit R, Geoffrois L, Sengelov L, Thalmann G, Charpentier D, Rolland F, Mignot L, Sundar S, Symonds P, Graham J, Joly F, Marreaud S, Collette L, Sylvester R; European Organisation for Research and Treatment of Cancer Genito-Urinary Cancers Group; Groupe d'Etude des Tumeurs Urogénitales; National Cancer Research Institute Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; German Association of Urologic Oncology.

Lancet Oncol. 2015 Jan;16(1):76-86. doi: 10.1016/S1470-2045(14)71160-X. Epub 2014 Dec 11.

PMID:
25498218
15.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
16.

[Advanced bladder cancer : From chemo- to immunotherapy].

Horn T, Krege S, Retz M.

Urologe A. 2018 Jun;57(6):686-692. doi: 10.1007/s00120-018-0626-2. Review. German.

PMID:
29637216
17.

PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer.

Stenehjem DD, Tran D, Nkrumah MA, Gupta S.

Onco Targets Ther. 2018 Sep 19;11:5973-5989. doi: 10.2147/OTT.S135157. eCollection 2018. Review.

18.

Surrogate end points for overall survival in trials of PD-(L)1 inhibitors for urinary cancers: a systematic review.

Abdel-Rahman O.

Immunotherapy. 2018 Feb;10(2):139-148. doi: 10.2217/imt-2017-0115. Review.

PMID:
29260622
19.

[Novel agents for the therapy of castration-resistant prostate cancer: overview of pivotal studies and new strategies to come].

Ouzaid I, Ravery V, Pouessel D, Culine S.

Prog Urol. 2013 Jan;23(1):1-7. doi: 10.1016/j.purol.2012.07.007. Epub 2012 Aug 13. Review. French.

PMID:
23287477
20.

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.

Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N.

Eur Urol. 2017 Apr;71(4):630-642. doi: 10.1016/j.eururo.2016.08.002. Epub 2016 Aug 31.

PMID:
27591931

Supplemental Content

Support Center